Search research articles
Contact Us
Filters
Showing results (91-100 of 141) with videos related to
Page
of 15
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 21, 2019
An <sup>18</sup>F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with <sup>18</sup>F-JK-PSMA-7 During the First Year of Application
Felix Dietlein, Melanie Hohberg, Carsten Kobe, et al.
EJNMMI Research
|
January 10, 2025
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy
Jan Heilinger, Katrin Sabine Roth, Henning Weis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2016
PSA-Stratified Performance of <sup>18</sup>F- and <sup>68</sup>Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
Felix Dietlein, Carsten Kobe, Stephan Neubauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 9, 2018
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
Jasmin Mettler, Horst Müller, Conrad-Amadeus Voltin, et al.
European Journal of Haematology
|
March 22, 2005
Imaging of central nervous system lymphomas with iodine-123 labeled rituximab
Markus Dietlein, Hendrik Pels, Holger Schulz, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 25, 2012
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib
Carsten Kobe, Matthias Scheffler, Arne Holstein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 9, 2011
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET
Deniz Kahraman, Matthias Scheffler, Thomas Zander, et al.
International Journal of Molecular Sciences
|
October 16, 2024
Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [<sup>131</sup>I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice
Thomas Fischer, Felix Dietlein, Detlev Bongartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody
Roland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2019
Intraindividual Comparison of <sup>18</sup>F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer
Felix Dietlein, Carsten Kobe, Melanie Hohberg, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 141) with videos related to
Sort By:
Page
of 15
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 21, 2019
An <sup>18</sup>F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with <sup>18</sup>F-JK-PSMA-7 During the First Year of Application
Felix Dietlein, Melanie Hohberg, Carsten Kobe, et al.
EJNMMI Research
|
January 10, 2025
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy
Jan Heilinger, Katrin Sabine Roth, Henning Weis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 3, 2016
PSA-Stratified Performance of <sup>18</sup>F- and <sup>68</sup>Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer
Felix Dietlein, Carsten Kobe, Stephan Neubauer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 9, 2018
Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
Jasmin Mettler, Horst Müller, Conrad-Amadeus Voltin, et al.
European Journal of Haematology
|
March 22, 2005
Imaging of central nervous system lymphomas with iodine-123 labeled rituximab
Markus Dietlein, Hendrik Pels, Holger Schulz, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
April 25, 2012
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib
Carsten Kobe, Matthias Scheffler, Arne Holstein, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 9, 2011
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET
Deniz Kahraman, Matthias Scheffler, Thomas Zander, et al.
International Journal of Molecular Sciences
|
October 16, 2024
Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [<sup>131</sup>I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice
Thomas Fischer, Felix Dietlein, Detlev Bongartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody
Roland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 20, 2019
Intraindividual Comparison of <sup>18</sup>F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer
Felix Dietlein, Carsten Kobe, Melanie Hohberg, et al.
Page
of 15